Related Experiment Video
Updated: Jul 19, 2026
02:28
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Defining remission in psoriatic arthritis
1Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093-0943, USA. akavanaugh@ucsd.edu
Clinical and Experimental Rheumatology
|November 7, 2006
Summary
Defining remission in psoriatic arthritis (PsA) is challenging due to disease heterogeneity. This paper outlines key principles for establishing remission criteria in PsA patients, aiming for improved treatment outcomes.
Area of Science:
- Rheumatology
- Immunology
- Clinical Medicine
Background:
- Growing interest in psoriatic arthritis (PsA) treatment approaches, spurred by new therapies.
- Treatment goals for PsA focus on maximizing patient outcomes.
- Defining remission in rheumatoid arthritis offers a precedent, but PsA presents unique challenges.
Purpose of the Study:
- To establish foundational principles for defining remission in psoriatic arthritis.
- To address the complexities of PsA heterogeneity and outcome measure validation.
- To guide future research in PsA remission criteria development.
Main Methods:
- Review of existing literature on arthritis treatment and remission definitions.
- Analysis of psoriatic arthritis disease manifestations and heterogeneity.
- Discussion of principles for validating outcome measures in PsA.
Main Results:
- Identification of key considerations for defining remission in PsA.
- Highlighting the challenges posed by diverse PsA symptoms.
- Emphasizing the need for validated outcome measures.
Conclusions:
- Establishing a clear definition of remission in PsA is crucial for optimizing patient care.
- A systematic approach is needed to develop and validate PsA remission criteria.
- Further research is required to refine remission definitions in psoriatic arthritis.
Related Concept Videos
01:17Introduction to Language of Pathophysiology ll
This lesson explores key terms that describe how diseases progress, their outcomes, and their distribution in populations.Diagnostic tests identify diseases and monitor treatment. These include blood and urine tests, biopsies, imaging (X-ray, MRI), and detection of infectious agents.Remission is a reduction or disappearance of symptoms.Exacerbation refers to the worsening of symptoms, such as increased wheezing during an asthma attack.A precipitating factor triggers an acute episode, while a...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...